YOLFTbeta
Akebia Ther

Akebia Ther

AKBA · NASDAQ · Healthcare / Drug Manufacturers - Specialty & Generic

0.4742USD-0.02 (-4.78%)

Price History

Full chart

Market Stats

Previous Close0.498
Open0.49
Day Range0.4522 – 0.4919
52-Week Range0.814 – 3.20
Volume3.88M
Market Cap254.66M
P/E (TTM)0.00
Forward P/E28.74
EPS-0.12
Dividend Yield0.00%
Beta0.19
50-Day Avg1.04
200-Day Avg1.26

About

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its product portfolio includes Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent (DD) and non-dialysis dependent (NDD) patients; and Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD and the treatment of iron deficiency anemia in adult patients with NDD-CKD. The company is also developing AKB-9090, which is in Phase 2 clinical trial for treating cardiac surgery-related acute kidney injury and acute respiratory distress syndrome; and AKB-10108 for the treatment of retinopathy of prematurity in neonates. The company has license and collaboration agreements with Tanabe Pharma Corporation for the development and commercialization of Vafseo in Japan and other Asian countries; Vafseo License and Collaboration Agreements; CSL Vifor Agreements; Averoa License Agreement; License Agreement with Panion & BF Biotech, Inc.; Cyclerion Therapeutics License Agreement; and Q32 Asset Purchase Agreement. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Company Details

  • SectorHealthcare
  • IndustryDrug Manufacturers - Specialty & Generic
  • CEOMr. John P. Butler MBA
  • Employees194
  • Headquarters180 Third Avenue, Waltham, MA, United States, 02451, USA
  • Websitehttps://www.akebia.com

Leadership

  • Mr. John P. Butler MBACEO, President & Director · b. 1964
  • Mr. Erik John Ostrowski M.B.A.Chief Business Officer, Senior VP, CFO & Treasurer · b. 1972
  • Dr. Steven Keith Burke M.D.Senior VP and Chief Research & Development Officer · b. 1961
  • Mr. Nicholas GrundSenior VP & Chief Commercial Officer · b. 1970
  • Mr. Richard C. MalabreSenior VP & Chief Accounting Officer · b. 1961
  • Dr. Justin McCue Ph.D.Senior VP & Chief Technology Officer
  • Mercedes CarrascoSenior Director of Investor & Corporate Communications
  • Ms. Carolyn M. RucciSenior VP, Chief Legal Officer & Secretary · b. 1981
  • Ms. Meredith BowmanSenior VP & Chief People Officer

Financials

Income Statement

Currency: USD2012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue--700.23K01.53M177.98M207.74M335.00M295.31M213.58M292.48M194.62M160.18M236.20M
Growth (%)----100.00%-+11495.05%+16.72%+61.26%-11.85%-27.68%+36.94%-33.46%-17.70%+47.46%
Cost of Revenue--23.26M96.00K115.78M617.00K7.68M145.34M295.91M153.39M22.50M74.15M63.18M39.46M
Gross Profit---23.26M-96.00K-114.25M177.37M200.06M189.66M-601.00K60.18M269.99M120.47M97.00M196.73M
Gross Margin---3322.18%--7443.00%99.65%96.30%56.62%-0.20%28.18%92.31%61.90%60.56%83.29%
Operating Expense--14.68M61.42M22.21M257.28M378.20M475.95M375.84M325.50M350.77M166.73M147.47M173.24M
Operating Income-8.52M-15.93M-37.94M-61.51M-136.46M-79.92M-178.14M-286.29M-376.44M-265.32M-80.78M-46.26M-50.47M23.50M
Operating Margin---5418.20%--8889.90%-44.90%-85.75%-85.46%-127.47%-124.23%-27.62%-23.77%-31.51%9.95%
EBITDA-8.52M-12.46M-37.89M-61.42M-136.16M-76.06M-175.72M-247.64M-342.85M-227.35M3.06M-8.27M-13.72M21.73M
EBITDA Margin---5411.20%--8870.62%-42.73%-84.58%-73.92%-116.10%-106.45%1.04%-4.25%-8.57%9.20%
Net Income-8.20M-13.17M-37.03M-60.72M-135.75M-76.91M-171.90M-279.66M-349.87M-244.87M-94.23M-51.92M-69.41M-5.34M
Net Income Margin---5288.81%--8843.45%-43.21%-82.75%-83.48%-118.48%-114.65%-32.22%-26.68%-43.33%-2.26%
R&D5.63M10.78M25.40M43.02M115.78M230.89M291.07M322.97M218.49M147.85M165.99M63.08M37.65M62.36M
R&D as % of Total Revenue--3627.08%-7543.00%129.73%140.11%96.41%73.99%69.23%56.75%32.41%23.51%26.40%
Interest Expense1.64M703.57K206.00K510.00K901.00K2.80M6.15M38.64M8.87M19.94M15.69M6.03M18.18M24.18M
Interest Expense % of Total Revenue--29.42%-58.70%1.57%2.96%11.54%3.00%9.33%5.36%3.10%11.35%10.24%

Balance Sheet

Currency: USD2012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets2.24M34.66M111.00M142.94M300.22M364.25M996.54M771.20M644.14M529.35M356.05M241.70M220.67M376.56M
Total Liabilities4.92M3.91M6.92M11.94M232.10M244.92M360.61M376.44M396.52M455.34M350.82M272.29M269.86M343.95M
Total Equity-2.68M30.76M104.08M131.00M68.12M119.33M635.93M394.76M247.62M74.01M5.23M-30.58M-49.19M32.61M
Cash1.64M21.22M32.78M49.78M187.34M70.16M104.64M147.71M229.09M149.80M90.47M42.92M51.87M184.84M
Total Debt-11.92K-14.00K14.00K-15.00M108.32M126.28M189.13M99.78M104.18M188.73M216.30M
Net Debt-1.64M-21.20M-32.78M-49.76M-187.34M-70.16M-89.64M-39.39M-102.81M39.33M9.32M61.26M136.86M31.45M

Cash Flow

Currency: USD2012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-7.21M-11.33M-27.48M-52.41M57.91M-56.16M-97.49M-257.44M-110.39M-252.97M-73.15M-23.38M-40.66M67.99M
Investing Cash Flow1.37M-11.42M-65.35M-13.69M12.71M-177.26M36.59M211.18M-40.00M39.94M-114.00K--33.00K-7.93M
Financing Cash Flow2.48M42.33M104.40M83.09M66.95M116.24M96.56M88.97M231.72M133.73M14.60M-25.21M49.66M72.93M
Capital Expenditure019.73K229.00K414.00K2.66M1.62M1.61M6.66M317.00K59.00K114.00K033.00K291.00K
Free Cash Flow-7.21M-11.35M-27.71M-52.82M55.24M-57.78M-99.10M-264.10M-110.70M-253.02M-73.27M-23.38M-40.69M67.99M
Dividends Paid--0000--------
FCF to OCF100.00%100.17%100.83%100.79%95.40%102.89%101.65%102.59%100.29%100.02%100.16%100.00%100.08%100.00%
Dividend Paid to FCF--0.00%0.00%0.00%0.00%--------

Earnings

Report DateMay 12, 2014Aug 11, 2014Nov 10, 2014Mar 4, 2015May 11, 2015Aug 11, 2015Nov 9, 2015Mar 14, 2016May 5, 2016Aug 8, 2016Nov 9, 2016Mar 6, 2017May 9, 2017Aug 8, 2017Nov 8, 2017Mar 12, 2018May 9, 2018Aug 8, 2018Nov 8, 2018Mar 26, 2019May 9, 2019Aug 8, 2019Nov 12, 2019Mar 10, 2020May 5, 2020Aug 10, 2020Nov 5, 2020Feb 25, 2021May 10, 2021Aug 5, 2021Nov 4, 2021Mar 1, 2022May 9, 2022Aug 4, 2022Nov 3, 2022Mar 9, 2023May 8, 2023Aug 25, 2023Nov 8, 2023Mar 14, 2024May 9, 2024Aug 8, 2024Nov 7, 2024Mar 12, 2025May 8, 2025Aug 7, 2025Nov 10, 2025Feb 26, 2026May 7, 2026Aug 5, 2026Nov 9, 2026
EPS Estimate-0.38-0.34-0.45-0.65-0.55-0.51-0.52-0.28-0.42-0.62-1.140.77-0.41-0.92-0.46-0.35-0.53-0.42-0.56-0.38-0.40-0.35-0.41-0.47-0.60-0.47-0.24-0.40-0.36-0.31-0.29-0.33-0.29-0.33-0.12-0.19-0.15-0.02-0.08-0.04-0.09-0.05-0.05-0.07-0.04-0.02-0.04-0.03-0.02-0.03-0.03
EPS Actual-4.35-0.39-0.47-0.52-0.53-0.40-0.68-0.66-0.70-0.95-0.96-0.99-1.15-0.53-0.490.25-0.48-0.60-0.46-0.93-0.62-0.49-0.46-0.79-0.47-0.44-0.42-0.60-0.45-0.51-0.34-0.40-0.350.23-0.29-0.04-0.14-0.06-0.080.00-0.08-0.04-0.10-0.100.020.030.00-0.05-0.03-0.02-
Surprise-1044.74%-14.71%-4.44%20.00%3.64%21.57%-30.77%-135.71%-66.67%-53.23%15.79%-228.57%-180.49%42.39%-6.52%171.43%9.43%-42.86%17.86%-144.74%-55.00%-40.00%-12.20%-68.09%21.67%6.38%-75.00%-50.00%-25.00%-64.52%-17.24%-21.21%-20.69%169.70%-141.67%78.95%6.67%-200.00%0.00%108.00%11.11%20.00%-100.00%-33.33%150.00%233.50%105.00%-66.67%-50.00%33.33%-
Timing-Pre-marketPre-marketPre-marketPre-marketAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-marketAfter-hoursAfter-hoursPre-marketPre-marketPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketPre-marketPre-marketPre-marketAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-market-Pre-marketAfter-hoursAfter-hours

Key Statistics & Ratios

Market Cap254.66M
Enterprise Value157.85M
Trailing P/E0.00
Forward P/E28.74
PEG Ratio0.00
Price / Sales1.16
Price / Book10.33
EPS-0.12
Book Value0.092
Revenue (TTM)219.06M
Gross Profit (TTM)178.40M
EBITDA-4.30M
Profit Margin-13.54%
Operating Margin-5.46%
Return on Equity-109.38%
Return on Assets-1.05%
Shares Outstanding277.11M
Shares Float270.60M
Beta0.19
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Strong Buy
Based on 4 analystsTarget 3.92
  • Strong Buy
    3
  • Buy
    1

Ownership Breakdown

Institutions
42.87%
Insiders
4.06%
Retail / Other
53.07%

Top Institutional Holders

  • BlackRock Inc
    18.69M6.75%
  • State Street Corp
    11.61M4.19%
  • Vanguard Capital Management, LLC
    11.17M4.03%
  • Geode Capital Management, LLC
    6.45M2.33%
  • The Goldman Sachs Group Inc
    3.60M1.30%
  • Millennium Management LLC
    3.20M1.15%
  • Citigroup Inc
    2.85M1.03%
  • Bank of America Corp
    2.76M1.00%
  • Two Sigma Investments LLC
    2.44M0.88%
  • Qube Research & Technologies
    2.40M0.86%
  • Vanguard Portfolio Management, LLC
    2.22M0.80%
  • Charles Schwab Investment Management Inc
    2.02M0.73%
  • Nantahala Capital Management, LLC
    2.00M0.72%
  • Northern Trust Corp
    1.95M0.70%

Top Fund Holders

  • Vanguard MStar Total Stk Mkt Idx Invest
    7.91M2.86%
  • iShares Russell 2000 ETF
    6.69M2.41%
  • Foord Global Equity (Lux) A
    3.79M1.37%
  • Fidelity Small Cap Index
    2.80M1.01%
  • iShares Russell 2000 Growth ETF
    2.19M0.79%
  • Fidelity Enhanced Small Cap Core ETF
    1.88M0.68%